Cosciens BiopharmaCSCIF -5.24%62 Current Ratio is 5.57 as of Mar. 2026, which is 15% above its 10-year median of 4.83. GuruFocus rates CSCIF with a GF Score™ of 62/100 and a GF Value™ of $2.35 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,417 Biotechnology companies, Cosciens Biopharma ranks better than 61.4% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cosciens Biopharma's current ratio for the quarter that ended in Mar. 2026 was 5.57.
Cosciens Biopharma has a current ratio of 5.57. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Cosciens Biopharma's Current Ratio or its related term are showing as below:
CSCIF'
s Current Ratio Range Over the Past 10 Years
Min: 0.76 Med: 4.83 Max: 22.49
Current: 5.57
During the past 13 years, Cosciens Biopharma's highest Current Ratio was 22.49. The lowest was 0.76. And the median was 4.83.
CSCIF's Current Ratio is ranked better than 61.4% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs CSCIF: 5.57
Cosciens Biopharma (OTCPK:CSCIF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Cosciens Biopharma Current Ratio Related Terms
Cosciens Biopharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSCIF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Cosciens Biopharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCIF) has a Current Ratio of 5.57 as of Mar. 2026. This is 15% above median its historical median of 4.83. Over the past decade, Cosciens Biopharma's Current Ratio has ranged from 0.76 to 22.49. According to the industry distribution chart, Cosciens Biopharma ranks #547 out of 1417 companies in the Biotechnology industry, placing it in the top 38.6%.
Is Cosciens Biopharma's Current Ratio too high?
Cosciens Biopharma's current Current Ratio of 5.57 is 15% above median its 10-year median of 4.83. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 22.49. The Biotechnology industry median Current Ratio is 3.89. Cosciens Biopharma's value of 5.57 is 43.2% above this industry median. Based on the distribution chart, Cosciens Biopharma ranks #547 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cosciens Biopharma has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #547 out of 1417 companies for Current Ratio. This puts Cosciens Biopharma in the upper half of its industry. The industry median Current Ratio is 3.89. Cosciens Biopharma's value of 5.57 is 43.2% above this benchmark. Historically, Cosciens Biopharma's own Current Ratio has ranged from 0.76 to 22.49 over the past decade. While the company's 10-year median is 4.83 vs. the industry median of 3.89, Cosciens Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosciens Biopharma's current Current Ratio of 5.57 is 43.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current Current Ratio is 5.57, which is 15% above median its own 10-year median of 4.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.35, compared to a current price of $1.99 — trading 15.3% below its estimated fair value. The current Current Ratio is 5.57, which is 15% above median its 10-year median of 4.83 and 43.2% above the Biotechnology industry median of 3.89. Cosciens Biopharma's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Current Ratio is 5.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $1.99 is trading 15.3% below its estimated GF Value™ of $2.35.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
Current Ratio: 5.57 (15% above median its 10-year median of 4.83)
GF Value™: $2.35 vs. price of $1.99 (15.3% below fair value)
Industry Position: 43.2% above the Biotechnology median (#547 of 1417)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
62GF Score
Get the complete analysis for CSCIF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
